Etoposide-mediated glioblastoma cell death: dependent or independent on the expression of its target, topoisomerase II alpha?


Sevim H. , Parkinson J. F. , McDonald K. L.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.137, no.11, pp.1705-1712, 2011 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 137 Issue: 11
  • Publication Date: 2011
  • Doi Number: 10.1007/s00432-011-1046-5
  • Title of Journal : JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Page Numbers: pp.1705-1712

Abstract

Treatments which significantly improve progression-free and overall survival for patients with relapsed glioblastoma (GBM) after the standard therapy are lacking. The Topoisomerase II (TopoII) enzyme is a key target of anticancer agents because of the important role it plays in transcription regulation and chromatin remodeling. A drug with strong topoisomerase-mediated anticancer activity is etoposide that is used in combination with carboplatin in patients with relapsed GBM. We hypothesized that tumors harboring high expression of TopoII alpha (TopoIIa) would be more sensitive to etoposide treatment.